TABLE III.
In Vivo Dose Response of PPTP Xenografts to Temozolomide
| Line description | Tumor type | Dose (mg/kg) | Median time to event | P-value | EFS T/C | Median RTV at end of study | Tumor volume T/Ca | Median group response | EFS activityb |
|---|---|---|---|---|---|---|---|---|---|
| KT-10 | Wilms | 66 | 70.9 | <0.001 | 7.6 | >4 | 0.00 | CR | Int |
| 44 | 25.5 | <0.001 | 2.7 | >4 | 0.13 | SD | Int | ||
| 22 | 23.1 | <0.001 | 2.5 | >4 | 0.22 | PD2 | Int | ||
| CHLA258 | Ewing | 66 | 18.1 | 0.156 | 1.2 | >4 | 0.72 | PD1 | Low |
| 44 | 14.6 | 0.871 | 0.9 | >4 | 1.03 | PD1 | Low | ||
| 22 | 15.6 | 0.551 | 1.0 | >4 | 1.00 | PD1 | Low | ||
| Rh28 | ALV RMS | 66 | >EP | <0.001 | >6.8 | 0.0 | 0.36 | MCR | High |
| 44 | >EP | <0.001 | >6.8 | 1.2 | 0.36 | CR | Int | ||
| 22 | 69.9 | <0.001 | 5.6 | >4 | 0.50 | CR | Int | ||
| GBM2 | Glioblastoma | 66 | >EP | 0.008 | >2.4 | 0.2 | 0.12 | MCR | High |
| 44 | >EP | 0.034 | >2.4 | 0.3 | 0.14 | MCR | High | ||
| 22 | >EP | 0.046 | >2.4 | 0.1 | 0.11 | MCR | High |
a
Tumor volume T/C value: Relative tumor volumes (RTV) for control (C) and treatment (T) mice were calculated at day 21 or when all mice in the control and treated groups still had measurable tumor volumes (if less than 21 days). The T/C value is the mean RTV for the treatment group divided by the mean RTV for the control group. High activity = T/C ≤ 0.15; Intermediate activity = T/C ≤ 0.45 but >0.15; and Low activity = T/C > 45.
b
Objective response measures are described in detail in the Supplemental Response Definitions. PD1 = Progressive disease with EFS T/C ≤ 1.5, and PD2 = Progressive disease with EFS T/C > 1.5.